GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
=== Germany === In November 2005, a German translation was launched by the publishing house Computec Media AG. The German edition was thinner than the English original, the covers were slightly changed and the ratings raised. In January 2007 it was changed to a bi-monthly schedule and in July 2007 it was finally shut down.
== History == A phase III trial for dasiglucagon was started in July 2017. In December 2017, Zealand (Copenhagen, Denmark) announced the initiation of a phase III trial for dasiglucagon, with the intention of submitting positive outcomes to the US Food and Drug Administration (FDA) in 2019. The FDA approved dasiglucagon based on evidence from two clinical trials conducted in adults with type 1 diabetes (169 participants) and one clinical trial conducted in pediatric participants older than six years with type 1 diabetes (31 participants). The trials were conducted in the following five countries: United States, Germany, Austria, Canada, and Slovenia. The same trials were used to assess the safety and efficacy of dasiglucagon: adult Trials A and B and pediatric Trial C. In all trials, participants were randomized into one of three groups: one group received dasiglucagon, one group received placebo, and one group received glucagon for injection (a similar drug that is FDA approved for the same purpose as dasiglucagon). In all groups, participants were given insulin to decrease their blood sugar to a low level (hypoglycemia). Subjects received a single injection of either dasiglucagon, placebo, or glucagon for injection, and the ability of the treatment to increase the participants' blood sugar was evaluated.
=== Burmese === Burmese soy sauce production is dated back to the Bagan Era in the 9th and 10th century. Scripts written in praise of pe ngan byar yay (ပဲငံပြာရည်, literally "bean fish sauce") were found. Thick soy sauce is called kya nyo (ကြာညို့, from Chinese jiàngyóu).
The Sanitary Commission for the Eradication of Hookworm Disease was a Rockefeller-funded campaign from 1909 to 1914 to study and treat hookworm disease in 11 Southern states. Hookworm was known as the "germ of laziness". In 1913, the foundation expanded its work with the Sanitary Commission abroad and set up the International Health Division (also known as International Health Board), which began the foundation's first international public health activities. The International Health Division conducted campaigns in public health and sanitation against malaria, yellow fever, and hookworm in areas throughout Europe, Latin America and the Caribbean including Italy, France, Venezuela, Mexico, and Puerto Rico, totaling fifty-two countries on six continents and twenty-nine islands. The first director was Wickliffe Rose, followed by F.F. Russell in 1923, Wilbur Sawyer in 1935, and George Strode in 1944. A number of notable physicians and field scientists worked on the international campaigns, including Lewis Hackett, Hideyo Noguchi, Juan Guiteras, George C. Payne, Livingston Farrand, Cornelius P. Rhoads, and William Bosworth Castle. In 1936, The Rockefeller Foundation received one of the first awarded Walter Reed Medals from The American Society of Tropical Medicine & Hygiene to recognize its study and control of Yellow Fever. The World Health Organization, seen as a successor to the IHD, was formed in 1948, and the IHD was subsumed by the larger Rockefeller Foundation in 1951, discontinuing its overseas work.
Sources: en.wikipedia.org
For example in the United States, bills on cosmetics, food packaging, and textiles meant to regulate PFAS failed to pass through Congress in 2022. In 2026, the UK increased testing for PFAS as part of a national plan to tackle the substances, which have prompted environmental and health concerns. The government says that by 2029 it wants to align more closely with regulations issued by the EU, which is looking to prohibit all non-essential uses.
=== 3 May === French president Emmanuel Macron announced he would consider sending French troops to Ukraine "if the Russians were to break through the front lines" or if Ukraine were to request it. In Donetsk Oblast, three people were killed by Russian attacks in Kurakhove and Chasiv Yar, while one person was killed in a separate attack in Kharkiv. In Russia, the governor of Belgorod Oblast claimed that two people were injured by Ukrainian drone strikes in Voznesenovka and Shebekino. The HUR claimed the destruction of two Russian locomotives by fire over the last few days: one in Orenburg, the other in Vladikavkaz. Ukrainian media also reported that the agency carried out a cyberattack on internet providers and mobile operators in Tatarstan. The SBU arrested a resident of Kharkiv on suspicion of spying for Russia. The FSB claimed to have "liquidated" an agent working for the HUR who was plotting to carry out terrorist attacks against "military and energy objects" in Moscow and Leningrad Oblasts. The US announced plans to purchase new sensors for the JDAM-ER for Ukraine, which are designed to locate and destroy Russian GPS jammers.
== Medical laboratory accreditation == Credibility of medical laboratories is paramount to the health and safety of the patients relying on the testing services provided by these labs. Credentialing agencies vary by country. The international standard in use today for the accreditation of medical laboratories is ISO 15189 - Medical laboratories - Requirements for quality and competence. In the United States, billions of dollars is spent on unaccredited lab tests, such as Laboratory developed tests which do not require accreditation or FDA approval; about a billion USD a year is spent on US autoimmune LDTs alone. Accreditation is performed by the Joint Commission, College of American Pathologists, AAB (American Association of Bioanalysts), and other state and federal agencies. Legislative guidelines are provided under CLIA 88 (Clinical Laboratory Improvement Amendments) which regulates Medical Laboratory testing and personnel. The accrediting body in Australia is NATA, where all laboratories must be NATA accredited to receive payment from Medicare. In France the accrediting body is the Comité français d'accréditation (COFRAC). In 2010, modification of legislation established ISO 15189 accreditation as an obligation for all clinical laboratories. In the United Arab Emirates, the Dubai Accreditation Department (DAC) is the accreditation body that is internationally recognised by the International Laboratory Accreditation Cooperation (ILAC) for many facilities and groups, including Medical Laboratories, Testing and Calibration Laboratories, and Inspection Bodies.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.